alendronate has been researched along with Disease Models, Animal in 181 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To summarize the recent development on chondroprotective effect of alendronate (ALN) on articular cartilage in osteoarthritis (OA)." | 8.88 | [Research progress of protective effects of alendronate on articular cartilage in osteoarthritis]. ( He, D; Luo, Y; Wei, Q; Yin, M, 2012) |
| "The purpose of this study was to evaluate the effects of alendronate on orthodontic tooth movement (OTM) and bone modelling/remodelling in an osteogenesis imperfecta (OI) mice model." | 8.31 | How does alendronate affect orthodontic tooth movement in osteogenesis imperfecta: an in vivo study on a mice model. ( Ahmida, A; Chen, PJ; Kalajzic, Z; Mehta, S; Wang, K; Yadav, S; Zhichao, F, 2023) |
| " Icariin (ICA), one of the main flavonoids from plants of the Epimedium genus, has been shown to ameliorate osteoporosis and improve bone health in preclinical studies." | 8.02 | Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis. ( Ha, TTM; Lai, TT; Nguyen, HVM; Pham, CV; Pham, TT; Phuong, TT; To, TT; Tran, LD; Trinh, DC; Winkler, C, 2021) |
| "Alendronate (Aln) has been the first-line drug for osteogenesis imperfecta (OI), while the comparable efficacy of Aln and strontium ranelate (SrR) remains unclear." | 8.02 | Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta. ( Chen, R; He, H; Ma, C; Shi, C; Sun, B; Wu, H; Zhang, Y, 2021) |
| "The present study aimed to investigate the effects of phosphatidylserine liposomes (PSLs) and phosphatidylserine liposomes containing alendronate (AL-PSLs) on the improvement of methylprednisolone (MP) induced osteoporosis in a rat model." | 7.96 | Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate. ( Alaeddini, M; Dehpour, AR; Doustimotlagh, AH; Eskandarynasab, M; Etemad-Moghadam, S; Goudarzi, R; Partoazar, A; Takzaree, N, 2020) |
| "Alendronate regulates the activity of osteoclasts and healing of osteoporosis." | 7.85 | Effects of alendronate on osteoporosis treatment and levels of related cytokines. ( Gao, GC; Liu, CT; Yuan, XJ, 2017) |
| "Alendronate (ALN) is a key therapeutic used to treat glucocorticoid-induced osteoporosis (GIOP), but may induce severe side effects." | 7.85 | Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine. ( Huang, J; Jiang, X; Qiu, T; Ren, H; Shen, G; Tang, J; Yang, Z; Yao, Z; Yu, X; Zhang, Z; Zhao, W, 2017) |
| "We report a direct comparison of receptor activator of nuclear factor kappa B ligand (RANKL) inhibition (RANK-Fc) with bisphosphonate treatment (alendronate, ALN) from infancy through early adulthood in a mouse model of osteogenesis imperfecta." | 7.78 | Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. ( Bargman, R; Boskey, AL; DiCarlo, E; Pleshko, N; Posham, R; Raggio, C, 2012) |
| "Zoledronic acid is associated with jaw osteonecrosis, whereas alendronate did not produce a condition sufficient for osteonecrosis after tooth extraction." | 7.77 | Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats. ( Azambuja, AA; Campos, MM; Cherubini, K; Maahs, MP; Salum, FG, 2011) |
| "To evaluate the effects of alendronate (ALN) on the subchondral bone quality and cartilage degeneration in the early phase of experimental model of osteoarthritis after anterior cruciate ligament transaction (ACLT)." | 7.77 | Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritis. ( Hu, H; Song, H; Tian, F; Zhang, L; Zhang, Y, 2011) |
| " At the end of the osteoporosis development period, MP rats were randomized to receive: vehicle (n= 7), genistein aglycone (5 mg x kg(-1) s." | 7.75 | Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate. ( Altavilla, D; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F, 2009) |
| "The effect of alendronate on osteoclast and osteoblast function was studied in a novel spine pseudarthrosis model in rats." | 7.72 | High-dose alendronate uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model. ( Cammisa, FP; Huang, RC; Khan, SN; Lane, JM; Myers, ER; Sama, AA; Sandhu, HS, 2004) |
| "A rat model was used to study the efficacy of alendronate therapy in inhibition of particle-induced periprosthetic osteolysis." | 7.71 | Inhibition of particulate debris-induced osteolysis by alendronate in a rat model. ( Barmada, R; Gonzalez, MH; Sladek, E; Thadani, PJ; Waxman, B, 2002) |
| "To evaluate the anti-osteoporosis effect of alendronate on bone in rat model." | 7.71 | [The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model]. ( Wang, X; Yang, Z; Yu, S, 2001) |
| " Nearly six-time enhancement of bioavailability was observed when alendronate was used in the nanoparticulate form in transdermal patches used with sonophoresis." | 5.56 | Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis. ( Huang, G; Li, B; Ma, Z; Qin, S, 2020) |
| "Periodontitis was induced by ligature in 60 Wistar rats randomized into the following groups: control (Group 1); PDT (Group 2); ALN 0." | 5.48 | Synergistic effect of photodynamic therapy and alendronate on alveolar bone loss in rats with ligature-induced periodontitis. ( Camacho-Alonso, F; Davia-Peña, RS; Martínez-Beneyto, Y; Merino, JJ; Tudela-Mulero, MR; Vilaplana-Vivo, C, 2018) |
| "Chronic back pain is one of the most important complications of postmenopausal osteoporosis." | 5.46 | Alendronate inhibits hyperalgesia and suppresses neuropeptide markers of pain in a mouse model of osteoporosis. ( Iino, T; Kato, S; Naito, Y; Nakagawa, T; Sudo, A; Wakabayashi, H, 2017) |
| "Methionine treatment could be beneficial for the treatment of postmenopausal osteoporosis." | 5.40 | Methionine down-regulates TLR4/MyD88/NF-κB signalling in osteoclast precursors to reduce bone loss during osteoporosis. ( Gupta, S; Khandelwal, M; Manglani, K; Surolia, A; Vijayan, V, 2014) |
| "Alendronate (ALN) can increase bone mass and improve the microstructure of osteoporotic vertebrae, which might be helpful in preserving disc morphology and mechanical properties." | 5.39 | Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats. ( Hu, QF; Luo, Y; Song, HP; Su, YL; Wang, WY; Zhang, L; Zhang, YZ, 2013) |
| "Alendronate treatment before fracture did not cause a significant increase in cartilage retention in fracture callus." | 5.39 | Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta. ( Begun, DL; Caird, MS; Goldstein, SA; Kozloff, KM; Marini, JC; McElderry, JD; Meganck, JA; Morris, MD; Swick, A, 2013) |
| "Osteoporosis is accompanied by predominantly metaphyseal fractures with a delayed and qualitatively reduced healing process." | 5.36 | Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis? ( Hoerster, AK; Kolios, L; Malcherek, MC; Rack, T; Sehmisch, S; Seidlova-Wuttke, D; Stuermer, EK; Stuermer, KM; Tezval, M; Wuttke, W, 2010) |
| "Losartan treatment, which lowers TGFβ signaling and restores aortic wall integrity in mice with mild MFS, did not mitigate bone loss in Fbn1(mgR/mgR) mice even though it ameliorated vascular disease." | 5.36 | Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. ( Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S, 2010) |
| "Tibial osteomyelitis was induced in 72 Wistar albino rats with Staphylococcus aureus ATCC 25923 strain." | 5.35 | Alendronate enhances antibiotic-impregnated bone grafts in the treatment of osteomyelitis. ( Aktekin, CN; Altay, M; Erdemli, E; Karahuseyinoglu, S; Korkusuz, F; Ozturk, AM; Tabak, AY, 2008) |
| " The high dosage of alendronate increased overall growth plate height, particularly within the hypertrophic zone, which suggests a failure of vascular invasion-induced apoptosis in the hypertrophic cells." | 5.32 | Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. ( Evans, KD; Lau, ST; Martin, RB; Oberbauer, AM, 2003) |
| "Alendronate (ALN) is a third generation bisphosphonate with demonstrated osteoclast inhibitory activity that may slow down the resorptive process after severe traumatic injuries." | 5.31 | Effect of topical alendronate on root resorption of dried replanted dog teeth. ( Bryson, EC; Caplan, D; Levin, L; Trope, M, 2001) |
| "Alendronate was administered to 6-week-old mice during a period of active growth at a dosage of 73 microg alendronate/kg/day for the first 4 weeks and 26 microg alendronate/kg/day for the next 4 weeks." | 5.31 | A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. ( Boskey, AL; Camacho, NP; Doty, SB; Ilg, WA; Raggio, CL; Root, L; Toledano, TR; Zraick, V, 2001) |
| "Alendronate is a third-generation bisphosphonate that blocks osteoclastic bone resorption." | 5.31 | Effects of alendronate on particle-induced osteolysis in a rat model. ( Allen, MJ; Bostrom, MP; Millett, PJ, 2002) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 5.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| "To summarize the recent development on chondroprotective effect of alendronate (ALN) on articular cartilage in osteoarthritis (OA)." | 4.88 | [Research progress of protective effects of alendronate on articular cartilage in osteoarthritis]. ( He, D; Luo, Y; Wei, Q; Yin, M, 2012) |
| "The purpose of this study was to evaluate the effects of alendronate on orthodontic tooth movement (OTM) and bone modelling/remodelling in an osteogenesis imperfecta (OI) mice model." | 4.31 | How does alendronate affect orthodontic tooth movement in osteogenesis imperfecta: an in vivo study on a mice model. ( Ahmida, A; Chen, PJ; Kalajzic, Z; Mehta, S; Wang, K; Yadav, S; Zhichao, F, 2023) |
| "Mechanical loading and alendronate (ALN) can be used as noninvasive physical therapy methods for osteoarthritis (OA)." | 4.31 | Axial Compressive Loading Attenuates Early Osteoarthritis by Reducing Subchondral Bone Remodeling. ( Cai, H; Fu, L; Li, G; Liu, C; Liu, Q; Liu, Y; Pan, Y; Wu, J; Yang, Q; Yu, Y; Zhong, J, 2023) |
| " Icariin (ICA), one of the main flavonoids from plants of the Epimedium genus, has been shown to ameliorate osteoporosis and improve bone health in preclinical studies." | 4.02 | Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis. ( Ha, TTM; Lai, TT; Nguyen, HVM; Pham, CV; Pham, TT; Phuong, TT; To, TT; Tran, LD; Trinh, DC; Winkler, C, 2021) |
| "Alendronate (Aln) has been the first-line drug for osteogenesis imperfecta (OI), while the comparable efficacy of Aln and strontium ranelate (SrR) remains unclear." | 4.02 | Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta. ( Chen, R; He, H; Ma, C; Shi, C; Sun, B; Wu, H; Zhang, Y, 2021) |
| "The present study aimed to investigate the effects of phosphatidylserine liposomes (PSLs) and phosphatidylserine liposomes containing alendronate (AL-PSLs) on the improvement of methylprednisolone (MP) induced osteoporosis in a rat model." | 3.96 | Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate. ( Alaeddini, M; Dehpour, AR; Doustimotlagh, AH; Eskandarynasab, M; Etemad-Moghadam, S; Goudarzi, R; Partoazar, A; Takzaree, N, 2020) |
| "Alendronate and raloxifene, a bisphosphonate and a selective estrogen modulator, respectively, are established osteoporosis therapies." | 3.88 | Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats. ( Faverani, LP; Freire, AR; Gruber, R; Hassumi, JS; Luvizuto, ER; Momesso, GAC; Okamoto, R; Polo, TOB; Prado, FB; Ramalho-Ferreira, G; Rossi, AC, 2018) |
| "Alendronate regulates the activity of osteoclasts and healing of osteoporosis." | 3.85 | Effects of alendronate on osteoporosis treatment and levels of related cytokines. ( Gao, GC; Liu, CT; Yuan, XJ, 2017) |
| "Alendronate (ALN) is a key therapeutic used to treat glucocorticoid-induced osteoporosis (GIOP), but may induce severe side effects." | 3.85 | Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine. ( Huang, J; Jiang, X; Qiu, T; Ren, H; Shen, G; Tang, J; Yang, Z; Yao, Z; Yu, X; Zhang, Z; Zhao, W, 2017) |
| " In the present study, we aimed to examine the efficacy and safety of alendronate (ALN) and teriparatide (TPD) for treating bone disorder in late-stage CKD with pre-existing secondary hyperparathyroidism using a rat model of CKD." | 3.85 | Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. ( Hamano, H; Hiratsuka, S; Iwasaki, N; Kameda, Y; Kanehira, Y; Kimura-Suda, H; Ota, M; Sato, D; Shimizu, T; Takahata, M, 2017) |
| "Combined therapy with BJD and alendronate can act synergistically against osteoporosis, which was possibly related to a reduced bone conversion rate through inhibiting bone resorption." | 3.85 | Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment. ( Guo, W; Huang, XH; Liang, RH; Su, L; Wang, CJ, 2017) |
| "Alendronate sodium (Fosamax) is most widely used for the prevention and treatment of osteoporosis." | 3.80 | An NMR metabolomic study on the effect of alendronate in ovariectomized mice. ( Chen, SY; Chiang, SS; Kao, JP; Mau, JL; Mishchuk, DO; Slupsky, CM; Yang, CC; Yu, HT, 2014) |
| "We report a direct comparison of receptor activator of nuclear factor kappa B ligand (RANKL) inhibition (RANK-Fc) with bisphosphonate treatment (alendronate, ALN) from infancy through early adulthood in a mouse model of osteogenesis imperfecta." | 3.78 | Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. ( Bargman, R; Boskey, AL; DiCarlo, E; Pleshko, N; Posham, R; Raggio, C, 2012) |
| "Alendronate is a nitrogen-containing bisphosphonate that is widely used for the treatment of osteoporosis." | 3.78 | Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: evaluation of transdermal absorption, safety, and pharmacological effects after application in rats. ( Hayashi, R; Hirai, Y; Hitomi, K; Kamiyama, F; Katsumi, H; Kusamori, K; Liu, S; Quan, YS; Sakane, T; Tanaka, Y; Yamamoto, A, 2012) |
| "To investigate the disease modifying effects of cathepsin K (CatK) inhibitor L-006235 compared to alendronate (ALN) in two preclinical models of osteoarthritis (OA)." | 3.78 | Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. ( Duong, LT; Hayami, T; Pickarski, M; Wesolowski, GA; Zhuo, Y, 2012) |
| "Zoledronic acid is associated with jaw osteonecrosis, whereas alendronate did not produce a condition sufficient for osteonecrosis after tooth extraction." | 3.77 | Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats. ( Azambuja, AA; Campos, MM; Cherubini, K; Maahs, MP; Salum, FG, 2011) |
| "To evaluate the effects of alendronate (ALN) on the subchondral bone quality and cartilage degeneration in the early phase of experimental model of osteoarthritis after anterior cruciate ligament transaction (ACLT)." | 3.77 | Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritis. ( Hu, H; Song, H; Tian, F; Zhang, L; Zhang, Y, 2011) |
| " Intravenous (IV) and intraperitoneal (IP) liposomal alendronate (LA) treatments have been shown to deplete circulating monocytes and peritoneal macrophages resulting in the inhibition of restenosis and endometriosis (EM), respectively." | 3.76 | Route of administration-dependent anti-inflammatory effect of liposomal alendronate. ( Afergan, E; Ben-David, M; Epstein, H; Golomb, G; Gutman, D; Haber, E; Koroukhov, N; Schachter, M, 2010) |
| "Alendronate is a known inhibitor of root resorption and the development of alendronate paste would enhance its utilization as intracanal medication." | 3.75 | Biocompatibility evaluation of alendronate paste in rat's subcutaneous tissue. ( Capaldi, ML; Castilho, LR; de Moraes, IG; Mori, GG; Nunes, DC; Poi, WR, 2009) |
| " At the end of the osteoporosis development period, MP rats were randomized to receive: vehicle (n= 7), genistein aglycone (5 mg x kg(-1) s." | 3.75 | Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate. ( Altavilla, D; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F, 2009) |
| " Then 5 rats were confirmed cases of osteoporosis and the remaining 60 were randomly divided into 4 groups 15 each: (1) control group with NS 8 ml x kg(-1) x w(-1); (2) alendronate group with alendronate 40 mg x kg(-1) x w(-1); (3) qianggu group with qianggu capsules 90 mg x kg(-1) x d(-1); (4) co-medicated group with alendronate 40 mg x kg(-1) x w(-1) and qianggu capsules 90 mg x kg(-1) x d(-1)." | 3.75 | [Skeletal biomechanical effectiveness of retinoic acid on induction of osteoporotic rats treated by alendronate and qianggu capsules]. ( Chen, H; Chen, L; Chen, LW; Guo, XS; Qi, DS; Xu, HZ; Zhang, GY, 2009) |
| " To clarify this, we investigated the effects of genistein compared with alendronate, raloxifene and oestradiol in an animal model of established osteoporosis." | 3.74 | Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol. ( Altavilla, D; Antoci, S; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Granese, R; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F, 2008) |
| " Recent data asserted that cell inflammation could be reversed by the addition of some isoprenoids, such as geranylgeraniol and farnesyl pyrophosphate." | 3.74 | Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency. ( De Leo, L; Decorti, G; Marcuzzi, A; Not, T; Pontillo, A; Tommasini, A; Ventura, A, 2008) |
| " Because this difference has been attributed to the antiapoptotic inflammatory signals that protect osteoclasts from BP-induced apoptosis, but not RANK antagonists, we tested the hypothesis that osteoprotegerin (OPG) is more effective in preventing wear debris-induced osteolysis than zoledronic acid (ZA) or alendronate (Aln) in the murine calvaria model using in vivo micro-CT and traditional histology." | 3.74 | Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. ( Awad, HA; Bechtold, CD; Bukata, SV; Hock, C; Ito, H; Nakamura, T; O'Keefe, RJ; Proulx, ST; Schwarz, EM; Tsutsumi, R, 2008) |
| " In the current study, FT-IRM and FT-IRIS were used to characterize bone mineralization in a mouse model of osteogenesis imperfecta (OI) after treatment with the bisphosphonate alendronate (ALN)." | 3.72 | Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice. ( Camacho, NP; Carroll, P; Raggio, CL, 2003) |
| "The effect of alendronate on osteoclast and osteoblast function was studied in a novel spine pseudarthrosis model in rats." | 3.72 | High-dose alendronate uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model. ( Cammisa, FP; Huang, RC; Khan, SN; Lane, JM; Myers, ER; Sama, AA; Sandhu, HS, 2004) |
| "A rat model was used to study the efficacy of alendronate therapy in inhibition of particle-induced periprosthetic osteolysis." | 3.71 | Inhibition of particulate debris-induced osteolysis by alendronate in a rat model. ( Barmada, R; Gonzalez, MH; Sladek, E; Thadani, PJ; Waxman, B, 2002) |
| "To evaluate the anti-osteoporosis effect of alendronate on bone in rat model." | 3.71 | [The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model]. ( Wang, X; Yang, Z; Yu, S, 2001) |
| " sinensis dosage (300 and 500 mg/kg/day) or alendronate had a positive effect on body weights, mechanical strength, BMD, and BMC compared to the other HLS groups." | 2.77 | Prevention of disuse osteoporosis in rats by Cordyceps sinensis extract. ( Cao, PC; Lei, W; Liu, D; Liu, N; Qi, W; Shi, L; Wu, ZX; Yan, YB; Zhang, Y, 2012) |
| "Osteoporosis is a worldwide healthcare challenge." | 1.62 | Investigating the Preventive Effects of 99Tc-Methylenediphosphonate on a Glucocorticoid-Induced Osteoporosis Rabbit Model. ( Cai, M; Chen, Y; Li, Y; Min, W; Wang, C; Wang, J; Yan, L; Zhang, R; Zhu, H, 2021) |
| " Nearly six-time enhancement of bioavailability was observed when alendronate was used in the nanoparticulate form in transdermal patches used with sonophoresis." | 1.56 | Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis. ( Huang, G; Li, B; Ma, Z; Qin, S, 2020) |
| "Ovariectomy induced bone loss and mechanical hyperalgesia in the hindlimbs with upregulation of CGRP expression in the DRG neurons innervating the hindlimbs." | 1.51 | Interleukin-6 Inhibitor Suppresses Hyperalgesia Without Improvement in Osteoporosis in a Mouse Pain Model of Osteoporosis. ( Kato, S; Miyamura, G; Nagao, N; Naito, Y; Sudo, A; Wakabayashi, H, 2019) |
| "Hajdu-Cheney syndrome (HCS) is a rare autosomal-dominant disorder primarily characterized by acro-osteolysis and early-onset osteoporosis." | 1.48 | High Bone Turnover in Mice Carrying a Pathogenic Notch2 Mutation Causing Hajdu-Cheney Syndrome. ( Amling, M; Cornils, K; Fehse, B; Hermans-Borgmeyer, I; Jeschke, A; Oheim, R; Rolvien, T; Schinke, T; Triviai, I; Vollersen, N; Yorgan, TA, 2018) |
| "Periodontitis was induced by ligature in 60 Wistar rats randomized into the following groups: control (Group 1); PDT (Group 2); ALN 0." | 1.48 | Synergistic effect of photodynamic therapy and alendronate on alveolar bone loss in rats with ligature-induced periodontitis. ( Camacho-Alonso, F; Davia-Peña, RS; Martínez-Beneyto, Y; Merino, JJ; Tudela-Mulero, MR; Vilaplana-Vivo, C, 2018) |
| "Osteoporosis is a global public health concern and, it can result from numerous pathogenic mechanisms, many of which are closely related with age, nutritional disorders, endocrine imbalance, or adverse drug side effects presented by glucocorticoids, heparin, and anti-epileptics." | 1.48 | Novel and rapid osteoporosis model established in zebrafish using high iron stress. ( Huang, Y; Leng, B; Li, X; Lin, J; Mei, X; Pan, Y; Qiu, J; Su, Y; Xing, C; Xu, J; Xue, Y; Zhang, W, 2018) |
| "Bisphosphonates (BP) are inhibitors of bone resorption and are used to treat postmenopausal osteoporosis." | 1.48 | Healing of fractures in osteoporotic bones in mice treated with bisphosphonates - A transcriptome analysis. ( Hauser, M; Hofstetter, W; Keller, I; Siegrist, M, 2018) |
| "Postmenopausal osteoporosis is a common disorder accompanied with estrogen deficiency in women." | 1.48 | In silico estrogen-like activity and in vivo osteoclastogenesis inhibitory effect of Cicer arietinum extract. ( Elfiky, AA; Sayed, AA, 2018) |
| "Even if postmenopausal osteoporosis is accompanied by diabetes in this animal model, both alendronate and raloxifene seem to show antiresorptive effects, decreased bone turnover rates, and improved bone mechanical strength." | 1.48 | Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model. ( Cho, DC; Gupta, R; Han, I; Kim, CH; Kim, KT; Kwon, JT; Lee, YS; Park, EK; Seo, YJ; Seu, SY; Sung, JK, 2018) |
| "Camurati-Engelmann disease (CED) is a genetic bone-modeling disorder mainly caused by mutations in the gene that encodes transforming growth factor-β1 (TGF-β1)." | 1.48 | Bone-targeted delivery of TGF-β type 1 receptor inhibitor rescues uncoupled bone remodeling in Camurati-Engelmann disease. ( Cao, X; Ding, Q; Ding, S; Qin, Y; Tang, S; Zhen, G, 2018) |
| "Loading induced cartilage pathology, osteophyte formation, and SCB changes; however, lower initial SCB mass and stiffness in B6 mice did not attenuate load-induced OA severity compared to FVB mice." | 1.46 | Role of subchondral bone properties and changes in development of load-induced osteoarthritis in mice. ( Adebayo, OO; Goldring, MB; Goldring, SR; Ko, FC; van der Meulen, MCH; Wan, PT; Wright, TM, 2017) |
| "Chronic back pain is one of the most important complications of postmenopausal osteoporosis." | 1.46 | Alendronate inhibits hyperalgesia and suppresses neuropeptide markers of pain in a mouse model of osteoporosis. ( Iino, T; Kato, S; Naito, Y; Nakagawa, T; Sudo, A; Wakabayashi, H, 2017) |
| " These results led us to hypothesize a mode of action by which presence of a linker is crucial in facilitating the anabolic effects of EP4a when dosed as a prodrug with ALN." | 1.43 | In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss. ( Chen, G; Grynpas, MD; Hu, S; Liu, CC; Willett, T; Young, RN, 2016) |
| "Alendronate caused an increase in the pain threshold value and inhibited c-Fos expression." | 1.42 | Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice. ( Abe, Y; Amizuka, N; Chiba, H; Iba, K; Kanaya, K; Kawamata, T; Oda, K; Sasaki, K; Sasaki, M; Yamashita, T, 2015) |
| "Methionine treatment could be beneficial for the treatment of postmenopausal osteoporosis." | 1.40 | Methionine down-regulates TLR4/MyD88/NF-κB signalling in osteoclast precursors to reduce bone loss during osteoporosis. ( Gupta, S; Khandelwal, M; Manglani, K; Surolia, A; Vijayan, V, 2014) |
| "Individual agents used to treat human osteoporosis reduce fracture risk by ∼ 50-60%." | 1.40 | Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass. ( Amugongo, SK; Dai, W; Dave, NK; Jia, J; Jiang, L; Lane, NE; Lay, YA; Li, CS; Olivera, D; Panganiban, B; Ritchie, RO; Walsh, D; Yao, W, 2014) |
| "Alendronate (ALN) can increase bone mass and improve the microstructure of osteoporotic vertebrae, which might be helpful in preserving disc morphology and mechanical properties." | 1.39 | Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats. ( Hu, QF; Luo, Y; Song, HP; Su, YL; Wang, WY; Zhang, L; Zhang, YZ, 2013) |
| "Alendronate treatment before fracture did not cause a significant increase in cartilage retention in fracture callus." | 1.39 | Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta. ( Begun, DL; Caird, MS; Goldstein, SA; Kozloff, KM; Marini, JC; McElderry, JD; Meganck, JA; Morris, MD; Swick, A, 2013) |
| " Here we disclose the pharmacokinetic profile of JTT-305/MK-5442 and its activity on bone remodeling in ovariectomized (OVX) osteopenic rats." | 1.38 | Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats. ( Cusick, T; Duong, L; Fisher, JE; Glantschnig, H; Karanam, B; Scott, K; Tijerina, M; Wei, N; Zhao, JZ, 2012) |
| "Alendronate was administered at 100 μg/kg, orally, once a day." | 1.38 | Downregulation of the inflammatory response by CORM-3 results in protective effects in a model of postmenopausal arthritis. ( Alcaraz, MJ; Caeiro, JR; Ferrándiz, ML; Guede, D; Ibáñez, L; Maicas, N; Motterlini, R, 2012) |
| "Alendronate was effective for radiologic, biomechanical, and histologic success of spine fusion in an osteoporotic animal model." | 1.37 | The influence of alendronate on spine fusion in an osteoporotic animal model. ( Boden, SD; Kawakami, M; Minamide, A; Nakao, S; Yoshida, M, 2011) |
| "Osteoporosis is accompanied by predominantly metaphyseal fractures with a delayed and qualitatively reduced healing process." | 1.36 | Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis? ( Hoerster, AK; Kolios, L; Malcherek, MC; Rack, T; Sehmisch, S; Seidlova-Wuttke, D; Stuermer, EK; Stuermer, KM; Tezval, M; Wuttke, W, 2010) |
| "We evaluated the efficacy of oral alendronate with different dosing regimens for non-nociceptive symptoms and osteoporosis in a sciatic nerve chronic constriction injury (CCI) model." | 1.36 | Effective dosage and administration schedule of oral alendronate for non-nociceptive symptoms in rats with chronic constriction injury. ( Hong, BY; Im, S; Ko, YJ; Lee, JI; Lim, SH; Park, GY; Park, JH, 2010) |
| "Alendronate treatment reduced bony osteophyte development." | 1.36 | In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. ( Doschak, MR; Jones, MD; Li, G; Maksymowych, WP; Tran, CW; Zernicke, RF, 2010) |
| "Losartan treatment, which lowers TGFβ signaling and restores aortic wall integrity in mice with mild MFS, did not mitigate bone loss in Fbn1(mgR/mgR) mice even though it ameliorated vascular disease." | 1.36 | Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. ( Carta, L; Cook, JR; Dietz, HC; Lee-Arteaga, S; Nistala, H; Ramirez, F; Rifkin, AN; Rifkin, DB; Siciliano, G; Smaldone, S, 2010) |
| "The arterial hypertension is a disorder characterized by relevant alterations in the bone tissue." | 1.35 | Local action of sodium alendronate in bone repair of spontaneously hypertensive rat (SHR). ( Chin, CM; Faig-Leite, H; Fernandes, RG; Nobre, MD, 2008) |
| " The purpose of our study was to verify the effect of laser therapy in combination with bisphosphonate on osteopenic bone structure." | 1.35 | Effect of low-power gallium-aluminum-arsenium laser therapy (830 nm) in combination with bisphosphonate treatment on osteopenic bone structure: an experimental animal study. ( de Melo Ocarino, N; de Oliveira Pereira, RD; Diniz, JS; do Carmo Magalhães, F; Nicolau, RA; Serakides, R, 2009) |
| " The clear dose-response effect may be viewed as a confirmation of the validity of the concept and encourages further study." | 1.35 | Peritoneal macrophage depletion by liposomal bisphosphonate attenuates endometriosis in the rat model. ( Danenberg, HD; Golomb, G; Haber, E; Koroukhov, N; Ron-El, R; Schachter, M, 2009) |
| "Otosclerosis is a bony dyscrasia characterized by histopathological findings of osteoclast production." | 1.35 | Medical treatment of otosclerosis: rationale for use of bisphosphonates. ( Brookler, K, 2008) |
| "Tibial osteomyelitis was induced in 72 Wistar albino rats with Staphylococcus aureus ATCC 25923 strain." | 1.35 | Alendronate enhances antibiotic-impregnated bone grafts in the treatment of osteomyelitis. ( Aktekin, CN; Altay, M; Erdemli, E; Karahuseyinoglu, S; Korkusuz, F; Ozturk, AM; Tabak, AY, 2008) |
| "Osteoporosis is a potential risk factor affecting implant stability following total joint arthroplasty." | 1.35 | Effect of preoperative combined treatment with alendronate and calcitriol on fixation of hydroxyapatite-coated implants in ovariectomized rats. ( Abu-Ali, S; Fotovati, A; Hayashi, K; Naito, M; Nakamura, Y, 2008) |
| "ALN suppressed trabecular bone resorption and endocortical bone erosion and formation and increased periosteal bone formation, while ALF increased the number of osteoblasts and suppressed trabecular bone resorption and markedly increased periosteal and endocortical bone formation." | 1.35 | Beneficial effects of combined administration of alendronate and alfacalcidol on cancellous bone mass of the tibia in orchidectomized rats: a bone histomorphometry study. ( Iwamoto, J; K Yeh, J; Matsumoto, H; Sato, Y; Takeda, T, 2008) |
| "Treatment with alendronate improved trabecular volume and number by reducing bone resorption, although bone formation was also reduced through coupling of bone remodeling." | 1.34 | Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture. ( Andresen, CJ; Bagi, CM; Berryman, E; Hanson, N; Moalli, M; Olson, E; Shen, V; Volberg, M, 2007) |
| "Alendronate or clodronate was applied for 3 days, and real-time PCR was performed to measure VEGF-A, VEGF-B, and VEGF-C and integrin-alphaV, integrin-beta1, and integrin-beta3." | 1.34 | Antiangiogenic effects of bisphosphonates on laser-induced choroidal neovascularization in mice. ( Honda, S; Imai, H; Nagai, T; Negi, A, 2007) |
| "Treatment with alendronate reduced the width of the fibrous loosening membrane and the number of osteoclasts at the bone-screw interface." | 1.33 | Alendronate inhibits bone resorption at the bone-screw interface. ( Azuma, Y; Miyaji, T; Nakase, T; Shimizu, N; Uchiyama, Y; Yoshikawa, H, 2005) |
| "Alendronate treatment in this study decreased fusion mass remodeling without inhibiting fusion rate." | 1.33 | The influence of alendronate treatment and bone graft volume on posterior lateral spine fusion in a porcine model. ( Bünger, C; Bünger, M; Christensen, FB; Egund, N; Li, H; Lind, M; Xue, Q; Zou, X, 2005) |
| "Alendronate treatment of OPG-/- mice resulted in enhancement of the volume of heterotopic new bone." | 1.33 | Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. ( Goto, S; Kameyama, Y; Kawai, T; Kimura, M; Maeda, H; Miyazawa, K; Tabuchi, M, 2005) |
| "When alendronate was injected at 3, 4, and 5 weeks, the bone mass increased by 70% and by 166% after 6 and 10 weeks, respectively, in comparison to the untreated control." | 1.32 | The influence of alendronate on bone formation and resorption in a rat ectopic bone development model. ( Bahar, H; Binderman, I; Kollerman, R; Yaffe, A, 2003) |
| " The high dosage of alendronate increased overall growth plate height, particularly within the hypertrophic zone, which suggests a failure of vascular invasion-induced apoptosis in the hypertrophic cells." | 1.32 | Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. ( Evans, KD; Lau, ST; Martin, RB; Oberbauer, AM, 2003) |
| "Alendronate-treated rats showed less bone resorption, but etanercept, intermittent parathyroid hormone treatment, or saline did not reduce the fluid pressure-induced bone resorption." | 1.32 | A rat model for testing pharmacologic treatments of pressure-related bone loss. ( Aspenberg, P; Astrand, J; Skoglund, B; Skripitz, R, 2003) |
| "The alendronate or saline was administered subcutaneously 1 week prior to surgery, immediately prior to surgery, and 1 week after surgery." | 1.32 | A histopathological investigation on the effect of systemic administration of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the rat mandible. ( Bostanci, H; Günhan, O; Kaynak, D; Meffert, R; Ozkaya, OG, 2003) |
| " Since ISA-13 is well absorbed through mucose tissues, we suggest that ISA-13 efficacy on reducing bone loss should be tested by its application on the mucosal tissue." | 1.31 | The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model. ( Binderman, I; Breuer, E; Golomb, G; Yaffe, A, 2000) |
| "Alendronate (ALN) is a third generation bisphosphonate with demonstrated osteoclast inhibitory activity that may slow down the resorptive process after severe traumatic injuries." | 1.31 | Effect of topical alendronate on root resorption of dried replanted dog teeth. ( Bryson, EC; Caplan, D; Levin, L; Trope, M, 2001) |
| "Alendronate was administered to 6-week-old mice during a period of active growth at a dosage of 73 microg alendronate/kg/day for the first 4 weeks and 26 microg alendronate/kg/day for the next 4 weeks." | 1.31 | A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. ( Boskey, AL; Camacho, NP; Doty, SB; Ilg, WA; Raggio, CL; Root, L; Toledano, TR; Zraick, V, 2001) |
| "Alendronate is a third-generation bisphosphonate that blocks osteoclastic bone resorption." | 1.31 | Effects of alendronate on particle-induced osteolysis in a rat model. ( Allen, MJ; Bostrom, MP; Millett, PJ, 2002) |
| "Instability-induced bone resorption therefore seems to be reduced by bisphosphonates, but higher doses are needed to obtain this effect than to reduce bone resorption associated with normal remodeling of untraumatized bone." | 1.31 | Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats. ( Aspenberg, P; Astrand, J, 2002) |
| "When the inhibition of bone resorption by calcitonin, osteoprotegerin, or alendronate is combined with the acute inhibition of bone mineralization with etidronate, the BRC model correctly predicts that there will no longer be a sharp rise in calcium and phosphate, and, therefore, there will no longer be the formation of the fetuin-mineral complex." | 1.31 | Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. ( Caputo, JM; Price, PA; Williamson, MK, 2002) |
| "Bisphosphonates suppress bone resorption by inhibiting the activity of mature osteoclasts as well as the formation of osteoclasts from bone marrow-derived precursor cells." | 1.30 | Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. ( Löwik, CW; Papapoulos, SE; van Beek, ER, 1997) |
| "Alendronate treatment by itself decreased osteocalcin by day 28 and resulted in a marginal decrease in serum total calcium on day 14." | 1.30 | Alendronate prevents cyclosporin A-induced osteopenia in the rat. ( Bowman, AR; Epstein, S; Jee, WS; Ma, Y; Sass, DA; Yuan, Z, 1997) |
| "Alendronate is a bisphosphonate that can decrease osteoclastic activity." | 1.30 | Alendronate did not inhibit instability-induced bone resorption. A study in rats. ( Aspenberg, P; Astrand, J, 1999) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 1.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| "Bone loss associated with postmenopausal osteoporosis can be reduced by treatment with antiresorptive agents such as estrogen or bisphosphonates." | 1.29 | Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. ( Black, EC; Bryant, HU; Chandrasekhar, S; Frolik, CA; Magee, DE, 1996) |
| "Alendronate treatment maintained all parameters of bone turnover at control (nonovariectomized) levels and prevented the bone loss in a dose-dependent manner." | 1.28 | The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. ( Clair, J; Davidson, J; Fioravanti, C; Frankenfield, D; Jackson, R; Klein, H; Quartuccio, H; Seedor, JG; Solomon, H; Thompson, DD, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (7.73) | 18.2507 |
| 2000's | 58 (32.04) | 29.6817 |
| 2010's | 93 (51.38) | 24.3611 |
| 2020's | 16 (8.84) | 2.80 |
| Authors | Studies |
|---|---|
| Shanas, N | 1 |
| Querido, W | 1 |
| Oswald, J | 1 |
| Jepsen, K | 1 |
| Carter, E | 1 |
| Raggio, C | 2 |
| Pleshko, N | 3 |
| Feng, P | 1 |
| Shu, S | 1 |
| Zhao, F | 1 |
| Larrañaga-Vera, A | 2 |
| Toti, KS | 2 |
| Flatow, JS | 2 |
| Haraczy, AJ | 2 |
| Warnick, E | 2 |
| Rao, H | 2 |
| Gao, ZG | 2 |
| Sussman, SM | 2 |
| Mediero, A | 2 |
| Leucht, P | 2 |
| Jacobson, KA | 2 |
| Cronstein, BN | 2 |
| Mehta, S | 1 |
| Wang, K | 1 |
| Chen, PJ | 1 |
| Zhichao, F | 1 |
| Ahmida, A | 1 |
| Kalajzic, Z | 1 |
| Yadav, S | 1 |
| Wu, J | 1 |
| Pan, Y | 2 |
| Yu, Y | 1 |
| Yang, Q | 1 |
| Liu, Q | 1 |
| Liu, Y | 3 |
| Zhong, J | 1 |
| Fu, L | 1 |
| Cai, H | 1 |
| Liu, C | 1 |
| Li, G | 2 |
| Lambova, SN | 1 |
| Ivanovska, N | 1 |
| Stoyanova, S | 1 |
| Belenska-Todorova, L | 1 |
| Georgieva, E | 1 |
| Batsalova, T | 1 |
| Moten, D | 1 |
| Apostolova, D | 1 |
| Dzhambazov, B | 1 |
| Scanu, A | 1 |
| Luisetto, R | 1 |
| Pavan, M | 1 |
| Guarise, C | 1 |
| Beninatto, R | 1 |
| Giraudo, C | 1 |
| Galuppini, F | 1 |
| Lazzarin, V | 1 |
| Guzzardo, V | 1 |
| Pennelli, G | 1 |
| Galesso, D | 1 |
| Masiero, S | 1 |
| Pham, CV | 1 |
| Pham, TT | 1 |
| Lai, TT | 1 |
| Trinh, DC | 1 |
| Nguyen, HVM | 1 |
| Ha, TTM | 1 |
| Phuong, TT | 1 |
| Tran, LD | 1 |
| Winkler, C | 1 |
| To, TT | 1 |
| Wu, H | 3 |
| Xu, T | 1 |
| Chen, Z | 1 |
| Wang, Y | 1 |
| Li, K | 1 |
| Chen, PS | 1 |
| Yao, Z | 3 |
| Su, J | 1 |
| Cheng, C | 1 |
| Wu, X | 1 |
| Zhang, H | 1 |
| Chai, Y | 1 |
| Zhang, X | 1 |
| Hu, Y | 2 |
| Yu, B | 2 |
| Cui, Z | 1 |
| Liu, S | 3 |
| Bi, J | 1 |
| Zhang, Y | 5 |
| Song, Q | 1 |
| Yu, M | 1 |
| Sun, X | 1 |
| Qu, D | 1 |
| Li, B | 2 |
| Huang, G | 1 |
| Ma, Z | 1 |
| Qin, S | 1 |
| Eskandarynasab, M | 1 |
| Doustimotlagh, AH | 1 |
| Takzaree, N | 1 |
| Etemad-Moghadam, S | 1 |
| Alaeddini, M | 1 |
| Dehpour, AR | 2 |
| Goudarzi, R | 1 |
| Partoazar, A | 1 |
| Luo, Y | 3 |
| Xu, D | 1 |
| Ke, X | 1 |
| Ci, T | 1 |
| Shi, C | 1 |
| Sun, B | 1 |
| Ma, C | 1 |
| Chen, R | 1 |
| He, H | 2 |
| van de Ven, CJJM | 1 |
| Bakker, NEC | 1 |
| Link, DP | 1 |
| Geven, EJW | 1 |
| Gossen, JA | 1 |
| Li, Y | 2 |
| Cai, M | 1 |
| Zhang, R | 1 |
| Wang, J | 2 |
| Zhu, H | 1 |
| Wang, C | 1 |
| Min, W | 1 |
| Chen, Y | 1 |
| Yan, L | 1 |
| Faverani, LP | 1 |
| Polo, TOB | 1 |
| Ramalho-Ferreira, G | 1 |
| Momesso, GAC | 1 |
| Hassumi, JS | 1 |
| Rossi, AC | 1 |
| Freire, AR | 1 |
| Prado, FB | 1 |
| Luvizuto, ER | 1 |
| Gruber, R | 1 |
| Okamoto, R | 1 |
| Liu, CT | 1 |
| Yuan, XJ | 1 |
| Gao, GC | 1 |
| Mostafavinia, A | 1 |
| Ahadi, R | 1 |
| Abdollahifar, M | 1 |
| Ghorishi, SK | 1 |
| Jalalifirouzkouhi, A | 1 |
| Bayat, M | 1 |
| Ahrens, BJ | 1 |
| Li, L | 1 |
| Ciminera, AK | 1 |
| Chea, J | 1 |
| Poku, E | 1 |
| Bading, JR | 1 |
| Weist, MR | 1 |
| Miller, MM | 1 |
| Colcher, DM | 1 |
| Shively, JE | 1 |
| Hou, T | 1 |
| Kolba, N | 1 |
| Guo, D | 1 |
| Yang, Y | 2 |
| Rong, X | 1 |
| Lv, X | 1 |
| Jiang, W | 1 |
| Lai, D | 1 |
| Xu, S | 1 |
| Fu, G | 1 |
| Kawada, S | 1 |
| Harada, A | 1 |
| Hashimoto, N | 1 |
| Vollersen, N | 1 |
| Hermans-Borgmeyer, I | 1 |
| Cornils, K | 1 |
| Fehse, B | 1 |
| Rolvien, T | 1 |
| Triviai, I | 1 |
| Jeschke, A | 1 |
| Oheim, R | 1 |
| Amling, M | 1 |
| Schinke, T | 1 |
| Yorgan, TA | 1 |
| Ren, H | 1 |
| Shen, G | 1 |
| Tang, J | 1 |
| Qiu, T | 1 |
| Zhang, Z | 1 |
| Zhao, W | 2 |
| Yu, X | 1 |
| Huang, J | 2 |
| Yang, Z | 2 |
| Jiang, X | 1 |
| Adebayo, OO | 1 |
| Ko, FC | 1 |
| Wan, PT | 1 |
| Goldring, SR | 1 |
| Goldring, MB | 1 |
| Wright, TM | 1 |
| van der Meulen, MCH | 1 |
| Özer, T | 1 |
| Aktas, A | 1 |
| Barıs, E | 1 |
| Çelik, HH | 1 |
| Vatansever, A | 1 |
| Camacho-Alonso, F | 1 |
| Davia-Peña, RS | 1 |
| Vilaplana-Vivo, C | 1 |
| Tudela-Mulero, MR | 1 |
| Merino, JJ | 1 |
| Martínez-Beneyto, Y | 1 |
| Zhang, W | 1 |
| Xu, J | 1 |
| Qiu, J | 1 |
| Xing, C | 1 |
| Li, X | 2 |
| Leng, B | 1 |
| Su, Y | 1 |
| Lin, J | 2 |
| Mei, X | 1 |
| Huang, Y | 1 |
| Xue, Y | 1 |
| Hauser, M | 1 |
| Siegrist, M | 1 |
| Keller, I | 1 |
| Hofstetter, W | 1 |
| Sayed, AA | 1 |
| Elfiky, AA | 1 |
| Lee, YS | 1 |
| Gupta, R | 1 |
| Kwon, JT | 1 |
| Cho, DC | 1 |
| Seo, YJ | 1 |
| Seu, SY | 1 |
| Park, EK | 1 |
| Han, I | 1 |
| Kim, CH | 1 |
| Sung, JK | 1 |
| Kim, KT | 1 |
| Geng, T | 1 |
| Chen, X | 1 |
| Zheng, M | 1 |
| Yu, H | 1 |
| Zhang, S | 1 |
| Sun, S | 1 |
| Guo, H | 1 |
| Jin, Q | 1 |
| Qin, Y | 1 |
| Tang, S | 1 |
| Zhen, G | 1 |
| Ding, Q | 1 |
| Ding, S | 1 |
| Cao, X | 2 |
| Zhu, J | 2 |
| Huo, Q | 1 |
| Xu, M | 1 |
| Yang, F | 1 |
| Shi, H | 1 |
| Niu, Y | 1 |
| Nakagawa, T | 2 |
| Wakabayashi, H | 3 |
| Naito, Y | 3 |
| Kato, S | 3 |
| Miyamura, G | 2 |
| Iino, T | 2 |
| Sudo, A | 3 |
| Nagao, N | 1 |
| Beattie, JR | 1 |
| Sophocleous, A | 1 |
| Caraher, MC | 1 |
| O'Driscoll, O | 1 |
| Cummins, NM | 1 |
| Bell, SEJ | 1 |
| Towler, M | 1 |
| Rahimnejad Yazdi, A | 1 |
| Ralston, SH | 1 |
| Idris, AI | 1 |
| Wang, Z | 1 |
| Zhao, Y | 1 |
| Zhang, D | 1 |
| Qi, B | 1 |
| Xiao, W | 1 |
| Hu, X | 1 |
| Yu, A | 1 |
| Parwin, A | 1 |
| Najmi, AK | 1 |
| Ismail, MV | 1 |
| Kaundal, M | 1 |
| Akhtar, M | 1 |
| Tomecka, MJ | 1 |
| Ethiraj, LP | 1 |
| Sánchez, LM | 1 |
| Roehl, HH | 1 |
| Carney, TJ | 1 |
| Von Schacht, E | 1 |
| Dambacher, MA | 1 |
| Ringe, JD | 1 |
| Dukas, L | 1 |
| Fu, LJ | 1 |
| Tang, TT | 1 |
| Hao, YQ | 1 |
| Dai, KR | 1 |
| Abtahi, J | 2 |
| Agholme, F | 3 |
| Aspenberg, P | 7 |
| Zhang, L | 2 |
| Wang, WY | 1 |
| Hu, QF | 1 |
| Song, HP | 1 |
| Su, YL | 1 |
| Zhang, YZ | 1 |
| Peled, E | 2 |
| Bejar, J | 1 |
| Barak, M | 1 |
| Orion, E | 1 |
| Norman, D | 2 |
| Hong, P | 1 |
| Boyd, D | 1 |
| Beyea, SD | 1 |
| Bezuhly, M | 1 |
| Berti-Couto, SA | 1 |
| Vasconcelos, AC | 1 |
| Iglesias, JE | 1 |
| Figueiredo, MA | 1 |
| Salum, FG | 2 |
| Cherubini, K | 2 |
| Derakhshanian, H | 1 |
| Djalali, M | 1 |
| Djazayery, A | 1 |
| Nourijelyani, K | 1 |
| Ghadbeigi, S | 1 |
| Pishva, H | 1 |
| Saedisomeolia, A | 1 |
| Bahremand, A | 1 |
| Meganck, JA | 1 |
| Begun, DL | 1 |
| McElderry, JD | 1 |
| Swick, A | 1 |
| Kozloff, KM | 1 |
| Goldstein, SA | 1 |
| Morris, MD | 1 |
| Marini, JC | 1 |
| Caird, MS | 1 |
| Vijayan, V | 1 |
| Khandelwal, M | 1 |
| Manglani, K | 1 |
| Gupta, S | 1 |
| Surolia, A | 1 |
| Elshal, MF | 1 |
| Almalki, AL | 1 |
| Hussein, HK | 1 |
| Khan, JA | 1 |
| Frick, KK | 1 |
| Asplin, JR | 1 |
| Culbertson, CD | 1 |
| Granja, I | 1 |
| Krieger, NS | 2 |
| Bushinsky, DA | 2 |
| Abe, Y | 1 |
| Iba, K | 1 |
| Sasaki, K | 1 |
| Chiba, H | 1 |
| Kanaya, K | 1 |
| Kawamata, T | 1 |
| Oda, K | 1 |
| Amizuka, N | 1 |
| Sasaki, M | 1 |
| Yamashita, T | 1 |
| Hazzaa, HH | 1 |
| Amin, G | 1 |
| Abo Hager, EA | 1 |
| El Shiekh, MA | 1 |
| Amugongo, SK | 1 |
| Yao, W | 1 |
| Jia, J | 1 |
| Lay, YA | 1 |
| Dai, W | 1 |
| Jiang, L | 1 |
| Walsh, D | 1 |
| Li, CS | 1 |
| Dave, NK | 1 |
| Olivera, D | 1 |
| Panganiban, B | 1 |
| Ritchie, RO | 1 |
| Lane, NE | 1 |
| Burwitz, BJ | 1 |
| Reed, JS | 1 |
| Hammond, KB | 1 |
| Ohme, MA | 1 |
| Planer, SL | 1 |
| Legasse, AW | 1 |
| Ericsen, AJ | 1 |
| Richter, Y | 1 |
| Golomb, G | 5 |
| Sacha, JB | 1 |
| Shah, NJ | 1 |
| Hyder, MN | 1 |
| Quadir, MA | 1 |
| Dorval Courchesne, NM | 1 |
| Seeherman, HJ | 1 |
| Nevins, M | 1 |
| Spector, M | 1 |
| Hammond, PT | 1 |
| Chen, SY | 1 |
| Yu, HT | 1 |
| Kao, JP | 1 |
| Yang, CC | 1 |
| Chiang, SS | 1 |
| Mishchuk, DO | 1 |
| Mau, JL | 1 |
| Slupsky, CM | 1 |
| Acerbo, AS | 1 |
| Kwaczala, AT | 1 |
| Yang, L | 1 |
| Judex, S | 1 |
| Miller, LM | 1 |
| Huh, JE | 1 |
| Kim, SJ | 1 |
| Kang, JW | 1 |
| Nam, DW | 1 |
| Choi, DY | 1 |
| Park, DS | 1 |
| Lee, JD | 1 |
| Khedgikar, V | 1 |
| Ahmad, N | 1 |
| Kushwaha, P | 1 |
| Gautam, J | 1 |
| Nagar, GK | 1 |
| Singh, D | 2 |
| Trivedi, PK | 1 |
| Mishra, PR | 1 |
| Sangwan, NS | 1 |
| Trivedi, R | 1 |
| Bae, J | 1 |
| Park, JW | 1 |
| Pasqualetti, S | 1 |
| Congiu, T | 1 |
| Banfi, G | 1 |
| Mariotti, M | 1 |
| Cankaya, D | 1 |
| Tabak, Y | 1 |
| Ozturk, AM | 2 |
| Gunay, MC | 1 |
| Boskey, AL | 5 |
| Marino, J | 1 |
| Spevak, L | 1 |
| Doty, S | 1 |
| Carter, EM | 1 |
| Raggio, CL | 5 |
| Hu, S | 1 |
| Liu, CC | 1 |
| Chen, G | 1 |
| Willett, T | 1 |
| Young, RN | 1 |
| Grynpas, MD | 1 |
| Tanaka, J | 1 |
| Kokuryo, S | 1 |
| Yoshiga, D | 1 |
| Tsurushima, H | 1 |
| Sakaguchi, O | 1 |
| Habu, M | 1 |
| Nishihara, T | 1 |
| Yoshioka, I | 1 |
| Tominaga, K | 1 |
| Ye, WL | 1 |
| Zhao, YP | 1 |
| Li, HQ | 1 |
| Na, R | 1 |
| Li, F | 1 |
| Mei, QB | 1 |
| Zhao, MG | 1 |
| Zhou, SY | 1 |
| Acar, N | 1 |
| Balkarli, H | 1 |
| Soyuncu, Y | 1 |
| Ozbey, O | 1 |
| Celik-Ozenci, C | 1 |
| Korkusuz, P | 1 |
| Ustunel, I | 1 |
| Lee, MY | 1 |
| Kim, HY | 1 |
| Yeo, SH | 1 |
| Baek, SY | 1 |
| Park, YK | 1 |
| Lee, CH | 1 |
| Conte, N | 1 |
| Spolidorio, LC | 3 |
| Andrade, CR | 2 |
| Esteves, JC | 1 |
| Marcantonio, E | 4 |
| Ota, M | 1 |
| Takahata, M | 1 |
| Shimizu, T | 1 |
| Kanehira, Y | 1 |
| Kimura-Suda, H | 1 |
| Kameda, Y | 1 |
| Hamano, H | 1 |
| Hiratsuka, S | 1 |
| Sato, D | 1 |
| Iwasaki, N | 1 |
| Huang, XH | 1 |
| Liang, RH | 1 |
| Su, L | 1 |
| Guo, W | 1 |
| Wang, CJ | 1 |
| Nobre, MD | 1 |
| Fernandes, RG | 1 |
| Chin, CM | 1 |
| Faig-Leite, H | 1 |
| Diniz, JS | 1 |
| Nicolau, RA | 1 |
| de Melo Ocarino, N | 1 |
| do Carmo Magalhães, F | 1 |
| de Oliveira Pereira, RD | 1 |
| Serakides, R | 1 |
| Bitto, A | 2 |
| Burnett, BP | 2 |
| Polito, F | 2 |
| Marini, H | 2 |
| Levy, RM | 2 |
| Armbruster, MA | 2 |
| Minutoli, L | 2 |
| Di Stefano, V | 2 |
| Irrera, N | 2 |
| Antoci, S | 1 |
| Granese, R | 1 |
| Squadrito, F | 2 |
| Altavilla, D | 2 |
| Hofstaetter, JG | 1 |
| Yan, J | 1 |
| Glimcher, MJ | 1 |
| Haber, E | 2 |
| Danenberg, HD | 2 |
| Koroukhov, N | 2 |
| Ron-El, R | 1 |
| Schachter, M | 2 |
| Brookler, K | 1 |
| Wang, X | 2 |
| Erickson, AM | 1 |
| Allen, MR | 3 |
| Burr, DB | 3 |
| Martin, RB | 2 |
| Hazelwood, SJ | 1 |
| Mori, GG | 1 |
| de Moraes, IG | 1 |
| Nunes, DC | 1 |
| Castilho, LR | 1 |
| Poi, WR | 1 |
| Capaldi, ML | 1 |
| Xue, Q | 3 |
| Li, H | 3 |
| Zou, X | 3 |
| Dalstra, M | 1 |
| Lind, M | 3 |
| Christensen, FB | 3 |
| Bünger, C | 3 |
| Ohishi, M | 1 |
| Chiusaroli, R | 1 |
| Ominsky, M | 1 |
| Asuncion, F | 1 |
| Thomas, C | 1 |
| Khatri, R | 1 |
| Kostenuik, P | 1 |
| Schipani, E | 1 |
| Diab, T | 1 |
| Koivunemi, A | 1 |
| Koivunemi, M | 1 |
| Kolios, L | 1 |
| Hoerster, AK | 1 |
| Sehmisch, S | 1 |
| Malcherek, MC | 1 |
| Rack, T | 1 |
| Tezval, M | 1 |
| Seidlova-Wuttke, D | 1 |
| Wuttke, W | 1 |
| Stuermer, KM | 1 |
| Stuermer, EK | 1 |
| Chen, L | 1 |
| Chen, LW | 1 |
| Chen, H | 1 |
| Guo, XS | 1 |
| Xu, HZ | 1 |
| Zhang, GY | 1 |
| Qi, DS | 1 |
| Anastassopoulos, G | 1 |
| Panteliou, S | 1 |
| Christopoulou, G | 1 |
| Stavropoulou, A | 1 |
| Panagiotopoulos, E | 1 |
| Lyritis, G | 1 |
| Khaldi, L | 1 |
| Varakis, J | 1 |
| Karamanos, N | 1 |
| Chen, BL | 1 |
| Xie, DH | 1 |
| Zheng, ZM | 1 |
| Lu, W | 1 |
| Ning, CY | 1 |
| Li, YQ | 1 |
| Li, FB | 1 |
| Liao, WM | 1 |
| Singh, S | 1 |
| Singh, V | 1 |
| Joshi, A | 1 |
| Im, S | 1 |
| Lim, SH | 1 |
| Lee, JI | 1 |
| Ko, YJ | 2 |
| Park, JH | 1 |
| Hong, BY | 1 |
| Park, GY | 1 |
| Jones, MD | 1 |
| Tran, CW | 1 |
| Maksymowych, WP | 1 |
| Zernicke, RF | 1 |
| Doschak, MR | 1 |
| Xiong, H | 1 |
| Wei, L | 1 |
| Zhang, C | 1 |
| Peng, B | 1 |
| Cottrell, JA | 1 |
| Vales, FM | 1 |
| Schachter, D | 1 |
| Wadsworth, S | 1 |
| Gundlapalli, R | 1 |
| Kapadia, R | 1 |
| O'Connor, JP | 1 |
| Fu, Q | 1 |
| Hu, SM | 1 |
| Yang, JJ | 1 |
| Hao, XJ | 1 |
| Zhu, B | 1 |
| Wang, Q | 1 |
| Wu, ZR | 1 |
| Li, J | 1 |
| Jindong, Z | 1 |
| Hai, T | 1 |
| Junchao, G | 1 |
| Bo, W | 1 |
| Qiang, WB | 1 |
| Afergan, E | 1 |
| Epstein, H | 2 |
| Gutman, D | 1 |
| Ben-David, M | 1 |
| Maahs, MP | 1 |
| Azambuja, AA | 1 |
| Campos, MM | 1 |
| Nistala, H | 1 |
| Lee-Arteaga, S | 1 |
| Carta, L | 1 |
| Cook, JR | 1 |
| Smaldone, S | 1 |
| Siciliano, G | 1 |
| Rifkin, AN | 1 |
| Dietz, HC | 1 |
| Rifkin, DB | 1 |
| Ramirez, F | 1 |
| Giro, G | 1 |
| Coelho, PG | 1 |
| Pereira, RM | 2 |
| Jorgetti, V | 2 |
| Orrico, SR | 1 |
| Nakao, S | 1 |
| Minamide, A | 1 |
| Kawakami, M | 1 |
| Boden, SD | 1 |
| Yoshida, M | 1 |
| Hu, H | 1 |
| Tian, F | 1 |
| Song, H | 1 |
| Lu, TL | 1 |
| Hu, HJ | 1 |
| Chen, T | 1 |
| Inose, H | 1 |
| Zhou, B | 1 |
| Yadav, VK | 1 |
| Guo, XE | 1 |
| Karsenty, G | 1 |
| Ducy, P | 1 |
| Ominsky, MS | 1 |
| Warmington, KS | 1 |
| Niu, QT | 1 |
| Asuncion, FJ | 1 |
| Barrero, M | 1 |
| Dwyer, D | 1 |
| Grisanti, M | 1 |
| Stolina, M | 1 |
| Kostenuik, PJ | 1 |
| Simonet, WS | 1 |
| Paszty, C | 1 |
| Ke, HZ | 1 |
| Bargman, R | 1 |
| Posham, R | 1 |
| DiCarlo, E | 1 |
| Wu, JB | 1 |
| Ho, HY | 1 |
| Lin, WC | 1 |
| Qi, W | 1 |
| Yan, YB | 1 |
| Lei, W | 1 |
| Wu, ZX | 1 |
| Liu, D | 1 |
| Shi, L | 1 |
| Cao, PC | 1 |
| Liu, N | 1 |
| Sandberg, O | 1 |
| Fisher, JE | 1 |
| Scott, K | 1 |
| Wei, N | 1 |
| Zhao, JZ | 1 |
| Cusick, T | 1 |
| Tijerina, M | 1 |
| Karanam, B | 1 |
| Duong, L | 1 |
| Glantschnig, H | 1 |
| Katsumi, H | 1 |
| Tanaka, Y | 1 |
| Hitomi, K | 1 |
| Hayashi, R | 1 |
| Hirai, Y | 1 |
| Kusamori, K | 1 |
| Quan, YS | 1 |
| Kamiyama, F | 1 |
| Sakane, T | 1 |
| Yamamoto, A | 1 |
| Hayami, T | 2 |
| Zhuo, Y | 1 |
| Wesolowski, GA | 2 |
| Pickarski, M | 2 |
| Duong, LT | 2 |
| Ibáñez, L | 1 |
| Alcaraz, MJ | 1 |
| Maicas, N | 1 |
| Guede, D | 1 |
| Caeiro, JR | 1 |
| Motterlini, R | 1 |
| Ferrándiz, ML | 1 |
| Niu, S | 1 |
| Zhu, Q | 1 |
| Zhen, P | 1 |
| Toker, H | 1 |
| Ozdemir, H | 1 |
| Ozer, H | 1 |
| Eren, K | 1 |
| Davis, M | 1 |
| Axelman, E | 1 |
| Nadir, Y | 1 |
| He, D | 1 |
| Yin, M | 1 |
| Wei, Q | 1 |
| van der Jagt, OP | 1 |
| Waarsing, JH | 1 |
| Kops, N | 1 |
| Schaden, W | 1 |
| Jahr, H | 1 |
| Verhaar, JA | 1 |
| Weinans, H | 1 |
| Conte Neto, N | 1 |
| S Bastos, A | 1 |
| Guimarães, M | 1 |
| McCarthy, EA | 1 |
| Hossack, MD | 1 |
| Miller, EA | 1 |
| Jain, S | 1 |
| Camacho, NP | 4 |
| Carroll, P | 1 |
| Yaffe, A | 3 |
| Kollerman, R | 1 |
| Bahar, H | 1 |
| Binderman, I | 3 |
| Evans, KD | 1 |
| Lau, ST | 1 |
| Oberbauer, AM | 1 |
| Astrand, J | 4 |
| Skripitz, R | 1 |
| Skoglund, B | 1 |
| Kaynak, D | 1 |
| Meffert, R | 1 |
| Bostanci, H | 1 |
| Günhan, O | 1 |
| Ozkaya, OG | 1 |
| Groothuis, A | 1 |
| Gao, J | 1 |
| Swaminathan, RV | 1 |
| Seifert, P | 1 |
| Edelman, ER | 1 |
| McLane, J | 1 |
| Bone, A | 1 |
| Destefano, J | 1 |
| Rodan, GA | 5 |
| Noa, M | 1 |
| Más, R | 1 |
| Mendoza, S | 1 |
| Gámez, R | 1 |
| Mendoza, N | 1 |
| Bünger, M | 2 |
| Egund, N | 2 |
| Sama, AA | 1 |
| Khan, SN | 1 |
| Myers, ER | 1 |
| Huang, RC | 1 |
| Cammisa, FP | 1 |
| Sandhu, HS | 1 |
| Lane, JM | 1 |
| Miyaji, T | 1 |
| Nakase, T | 1 |
| Azuma, Y | 2 |
| Shimizu, N | 1 |
| Uchiyama, Y | 1 |
| Yoshikawa, H | 2 |
| Misof, BM | 1 |
| Roschger, P | 1 |
| Baldini, T | 1 |
| Zraick, V | 2 |
| Root, L | 2 |
| Klaushofer, K | 1 |
| Fratzl, P | 1 |
| Shimshi, M | 1 |
| Abe, E | 1 |
| Fisher, EA | 1 |
| Zaidi, M | 1 |
| Fallon, JT | 1 |
| Liu, ZP | 1 |
| Li, WX | 1 |
| Sun, J | 1 |
| Huo, JS | 1 |
| Liu, CX | 1 |
| Zhang, Q | 1 |
| Badell, IR | 1 |
| Schwarz, EM | 3 |
| Boulukos, KE | 1 |
| Boyce, BF | 1 |
| Xing, L | 1 |
| Tabuchi, M | 1 |
| Miyazawa, K | 1 |
| Kimura, M | 1 |
| Maeda, H | 1 |
| Kawai, T | 1 |
| Kameyama, Y | 1 |
| Goto, S | 1 |
| Bagi, CM | 1 |
| Volberg, M | 1 |
| Moalli, M | 1 |
| Shen, V | 1 |
| Olson, E | 1 |
| Hanson, N | 1 |
| Berryman, E | 1 |
| Andresen, CJ | 1 |
| Tabak, AY | 1 |
| Aktekin, CN | 1 |
| Altay, M | 1 |
| Erdemli, E | 1 |
| Karahuseyinoglu, S | 1 |
| Korkusuz, F | 1 |
| Spolidorio, DM | 1 |
| Nassar, CA | 1 |
| Nassar, PO | 1 |
| Marcantonio, RA | 1 |
| Rossa, C | 1 |
| Nagai, T | 1 |
| Imai, H | 1 |
| Honda, S | 1 |
| Negi, A | 1 |
| Nishii, T | 1 |
| Hashimoto, J | 1 |
| Miki, H | 1 |
| Sugano, N | 1 |
| Ding, M | 1 |
| Danielsen, CC | 1 |
| Hvid, I | 1 |
| Mawatari, T | 1 |
| Miura, H | 1 |
| Iwamoto, Y | 1 |
| Higaki, H | 1 |
| Nakamura, Y | 1 |
| Hayashi, K | 1 |
| Abu-Ali, S | 1 |
| Naito, M | 1 |
| Fotovati, A | 1 |
| Iwamoto, J | 1 |
| Takeda, T | 1 |
| Matsumoto, H | 1 |
| Sato, Y | 1 |
| K Yeh, J | 1 |
| Marcuzzi, A | 1 |
| Pontillo, A | 1 |
| De Leo, L | 1 |
| Tommasini, A | 1 |
| Decorti, G | 1 |
| Not, T | 1 |
| Ventura, A | 1 |
| Tsutsumi, R | 1 |
| Hock, C | 1 |
| Bechtold, CD | 1 |
| Proulx, ST | 1 |
| Bukata, SV | 1 |
| Ito, H | 1 |
| Awad, HA | 1 |
| Nakamura, T | 1 |
| O'Keefe, RJ | 1 |
| Viera-Negrón, YE | 1 |
| Ruan, WH | 1 |
| Winger, JN | 1 |
| Hou, X | 1 |
| Sharawy, MM | 1 |
| Borke, JL | 1 |
| Sato, H | 1 |
| Oue, Y | 1 |
| Okabe, K | 1 |
| Ohta, T | 1 |
| Tsuchimoto, M | 1 |
| Kiyoki, M | 1 |
| Reddy, MS | 1 |
| Weatherford, TW | 1 |
| Smith, CA | 1 |
| West, BD | 1 |
| Jeffcoat, MK | 1 |
| Jacks, TM | 1 |
| Yamamoto, M | 1 |
| Markatos, A | 1 |
| Seedor, JG | 4 |
| Masarachia, P | 1 |
| Gentile, M | 1 |
| Balena, R | 2 |
| Antic, VN | 1 |
| Fleisch, H | 1 |
| Mühlbauer, RC | 1 |
| Frolik, CA | 1 |
| Bryant, HU | 1 |
| Black, EC | 1 |
| Magee, DE | 1 |
| Chandrasekhar, S | 1 |
| van Beek, ER | 1 |
| Löwik, CW | 1 |
| Papapoulos, SE | 1 |
| Sass, DA | 1 |
| Bowman, AR | 1 |
| Yuan, Z | 1 |
| Ma, Y | 1 |
| Jee, WS | 1 |
| Epstein, S | 1 |
| Meunier, PJ | 1 |
| Boivin, G | 1 |
| Neumann, KJ | 1 |
| Asplin, J | 1 |
| Adut, M | 1 |
| Breuer, E | 1 |
| Benz, EB | 1 |
| Lu, AP | 1 |
| Goater, JJ | 1 |
| Mollano, AV | 1 |
| Rosier, RN | 1 |
| Puzas, JE | 1 |
| Okeefe, RJ | 1 |
| da Paz, LH | 1 |
| de Falco, V | 1 |
| Teng, NC | 1 |
| dos Reis, LM | 1 |
| Levin, L | 1 |
| Bryson, EC | 1 |
| Caplan, D | 1 |
| Trope, M | 1 |
| Doty, SB | 1 |
| Ilg, WA | 1 |
| Toledano, TR | 1 |
| Frenkel, SR | 1 |
| Jaffe, WL | 1 |
| Valle, CD | 1 |
| Jazrawi, L | 1 |
| Maurer, S | 1 |
| Baitner, A | 1 |
| Wright, K | 1 |
| Sala, D | 1 |
| Hawkins, M | 1 |
| Di Cesare, PE | 1 |
| Sun, JS | 1 |
| Huang, YC | 1 |
| Tsuang, YH | 1 |
| Chen, LT | 1 |
| Lin, FH | 1 |
| Thadani, PJ | 1 |
| Waxman, B | 1 |
| Sladek, E | 1 |
| Barmada, R | 1 |
| Gonzalez, MH | 1 |
| Yu, S | 1 |
| Millett, PJ | 1 |
| Allen, MJ | 1 |
| Bostrom, MP | 1 |
| Price, PA | 1 |
| Caputo, JM | 1 |
| Williamson, MK | 1 |
| Thompson, DD | 2 |
| Quartuccio, H | 1 |
| Solomon, H | 1 |
| Fioravanti, C | 1 |
| Davidson, J | 1 |
| Klein, H | 1 |
| Jackson, R | 1 |
| Clair, J | 1 |
| Frankenfield, D | 1 |
| Grasser, W | 1 |
| Rosenblatt, M | 1 |
7 reviews available for alendronate and Disease Models, Animal
| Article | Year |
|---|---|
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
Topics: Aged; Alendronate; Animals; Bone Density; Disease Models, Animal; Drug Combinations; Drug Interactio | 2012 |
Enhancement of bone consolidation in mandibular distraction osteogenesis: a contemporary review of experimental studies involving adjuvant therapies.
Topics: Adjuvants, Pharmaceutic; Alendronate; Animals; Bone Morphogenetic Protein 4; Bone Regeneration; Dise | 2013 |
[Research progress of protective effects of alendronate on articular cartilage in osteoarthritis].
Topics: Alendronate; Animals; Anterior Cruciate Ligament; Bone Density Conservation Agents; Bone Remodeling; | 2012 |
[Bisphosphonate treatment in osteonecrosis of the femoral head].
Topics: Alendronate; Animals; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Di | 2007 |
[Assessment of bone quality. Effects of osteoporosis medications on structural and mechanical integrity of bone].
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservati | 2008 |
Preclinical pharmacology of alendronate.
Topics: Alendronate; Animals; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Estrogens; | 1993 |
Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Calcifi | 1997 |
1 trial available for alendronate and Disease Models, Animal
| Article | Year |
|---|---|
Prevention of disuse osteoporosis in rats by Cordyceps sinensis extract.
Topics: Alendronate; Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; C | 2012 |
173 other studies available for alendronate and Disease Models, Animal
| Article | Year |
|---|---|
Infrared Spectroscopy-Determined Bone Compositional Changes Associated with Anti-Resorptive Treatment of the
Topics: Alendronate; Animals; Bone and Bones; Disease Models, Animal; Mice; Minerals; Osteogenesis Imperfect | 2022 |
Anti-osteoporosis Effect of Fisetin against Ovariectomy Induced Osteoporosis in Rats: In silico, in vitro and in vivo Activity.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Antioxidants; Bone Density; Cell Line; Cell Prolifer | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
How does alendronate affect orthodontic tooth movement in osteogenesis imperfecta: an in vivo study on a mice model.
Topics: Alendronate; Animals; Bone Remodeling; Collagen; Disease Models, Animal; Female; Male; Mice; Osteocl | 2023 |
Axial Compressive Loading Attenuates Early Osteoarthritis by Reducing Subchondral Bone Remodeling.
Topics: Alendronate; Animals; Bone Remodeling; Cartilage, Articular; Disease Models, Animal; Inflammation; M | 2023 |
Changes in the Subchondral Bone, Visfatin, and Cartilage Biomarkers after Pharmacological Treatment of Experimental Osteoarthritis with Metformin and Alendronate.
Topics: Alendronate; Animals; Biomarkers; Cartilage, Articular; Disease Models, Animal; Metformin; Mice; Nic | 2023 |
Effect of intra-articular injection of a hyaluronic acid-alendronate conjugate on post-traumatic osteoarthritis induced by destabilization of the medial meniscus in rats.
Topics: Alendronate; Animals; Cartilage, Articular; Disease Models, Animal; Hyaluronic Acid; Injections, Int | 2023 |
Icariin reduces bone loss in a Rankl-induced transgenic medaka (Oryzias latipes) model for osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Disease Models, Animal; Etidronic Acid; Fish | 2021 |
Specific inhibition of FAK signaling attenuates subchondral bone deterioration and articular cartilage degeneration during osteoarthritis pathogenesis.
Topics: Alendronate; Animals; Anterior Cruciate Ligament; Bone and Bones; Bone Remodeling; Cartilage, Articu | 2020 |
Preliminary study on the electromagnetic field treatment of osteoporosis in rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Female | 2020 |
Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis.
Topics: Administration, Cutaneous; Alendronate; Animals; Biological Availability; Bone Density Conservation | 2020 |
Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Disease Models | 2020 |
Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors.
Topics: Alendronate; Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolif | 2020 |
Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Model | 2021 |
Sustained release of ancillary amounts of testosterone and alendronate from PLGA coated pericard membranes and implants to improve bone healing.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Coated Mate | 2021 |
Investigating the Preventive Effects of 99Tc-Methylenediphosphonate on a Glucocorticoid-Induced Osteoporosis Rabbit Model.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium Carbonate; Diphosphonates; Disease M | 2021 |
Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats.
Topics: Alendronate; Animals; Bone Density; Dental Implants; Disease Models, Animal; Female; Immunoenzyme Te | 2018 |
Effects of alendronate on osteoporosis treatment and levels of related cytokines.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Cytokines; Dis | 2017 |
Evaluation of the Effects of Photobiomodulation on Biomechanical Properties and Hounsfield Unit of Partial Osteotomy Healing in an Experimental Rat Model of Type I Diabetes and Osteoporosis.
Topics: Alendronate; Animals; Biomechanical Phenomena; Blood Glucose; Diabetes Mellitus, Type 1; Disease Mod | 2017 |
Diagnostic PET Imaging of Mammary Microcalcifications Using
Topics: Alendronate; Animals; Calcinosis; Cell Line, Tumor; Copper Radioisotopes; Disease Models, Animal; Fe | 2017 |
Desalted Duck Egg White Peptides Promote Calcium Uptake and Modulate Bone Formation in the Retinoic Acid-Induced Bone Loss Rat and Caco-2 Cell Model.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic; | 2017 |
Inhibition of mevalonate pathway prevents ischemia-induced cardiac dysfunction in rats via RhoA-independent signaling pathway.
Topics: Alendronate; Animals; Calcium Signaling; Calcium-Binding Proteins; Cardiomyopathy, Dilated; Cell Lin | 2017 |
Impairment of cold injury-induced muscle regeneration in mice receiving a combination of bone fracture and alendronate treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Cold Injury; Disease Models, Animal; Fractur | 2017 |
High Bone Turnover in Mice Carrying a Pathogenic Notch2 Mutation Causing Hajdu-Cheney Syndrome.
Topics: Adult; Alendronate; Animals; Base Sequence; Bone Diseases, Metabolic; Bone Marrow Cells; Bone Remode | 2018 |
Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine.
Topics: Alendronate; Animals; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bo | 2017 |
Role of subchondral bone properties and changes in development of load-induced osteoarthritis in mice.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cancellous Bo | 2017 |
Effects of local alendronate administration on bone defect healing. Histomorphometric and radiological evaluation in a rabbit model.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Regeneration; Disease Models, Animal; F | 2017 |
Synergistic effect of photodynamic therapy and alendronate on alveolar bone loss in rats with ligature-induced periodontitis.
Topics: Alendronate; Alveolar Bone Loss; Animals; Bone Density; Disease Models, Animal; Drug Combinations; D | 2018 |
Novel and rapid osteoporosis model established in zebrafish using high iron stress.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Calcification, Physiologic; | 2018 |
Healing of fractures in osteoporotic bones in mice treated with bisphosphonates - A transcriptome analysis.
Topics: Alendronate; Animals; Biomarkers; Bone Resorption; Cluster Analysis; Diphosphonates; Disease Models, | 2018 |
In silico estrogen-like activity and in vivo osteoclastogenesis inhibitory effect of Cicer arietinum extract.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Calcium-Binding Proteins; Cicer; Disease Mod | 2018 |
Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
Topics: Alendronate; Animals; Biomarkers; Bone Density; Bone Remodeling; Collagen Type I; Diabetes Mellitus, | 2018 |
Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice.
Topics: Aged; Alendronate; Animals; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Female; Hum | 2018 |
Bone-targeted delivery of TGF-β type 1 receptor inhibitor rescues uncoupled bone remodeling in Camurati-Engelmann disease.
Topics: Alendronate; Animals; Bone Remodeling; Camurati-Engelmann Syndrome; Cells, Cultured; Disease Models, | 2018 |
Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Bortezomib; Breast Neoplasms; Catechols | 2018 |
The effects of bisphosphonate on pain-related behavior and immunohistochemical analyses in hindlimb-unloaded mice.
Topics: Alendronate; Animals; Behavior, Animal; Bone Density Conservation Agents; Disease Models, Animal; Hi | 2018 |
Interleukin-6 Inhibitor Suppresses Hyperalgesia Without Improvement in Osteoporosis in a Mouse Pain Model of Osteoporosis.
Topics: Alendronate; Animals; Antibodies; Behavior, Animal; Bone Density Conservation Agents; Combined Modal | 2019 |
Raman spectroscopy as a predictive tool for monitoring osteoporosis therapy in a rat model of postmenopausal osteoporosis.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Disease Models, A | 2019 |
A novel hybrid compound LLP2A-alendronate accelerates open fracture healing in a rabbit model.
Topics: Alendronate; Animals; Dipeptides; Disease Models, Animal; Female; Fracture Healing; Male; Neovascula | 2019 |
Protective effects of alendronate in Triton X-100-induced hyperlipidemia in rats.
Topics: Alanine Transaminase; Alendronate; Animals; Aspartate Aminotransferases; Cholesterol, HDL; Cholester | 2019 |
Clinical pathologies of bone fracture modelled in zebrafish.
Topics: Alendronate; Animal Fins; Animals; Bony Callus; Diphosphonates; Disease Models, Animal; Fracture Hea | 2019 |
Long-term effects of alendronate on fracture healing and bone remodeling of femoral shaft in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Disease Models, Animal; Dru | 2013 |
Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; | 2013 |
Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Co | 2013 |
Core decompression and alendronate treatment of the osteonecrotic rat femoral head: computer-assisted analysis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Combined Modality Therapy; Decompression, Su | 2013 |
Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: a study in Wistar rats.
Topics: Adrenal Cortex Hormones; Alendronate; Animals; Biopsy, Needle; Bisphosphonate-Associated Osteonecros | 2014 |
Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate.
Topics: Alendronate; Animals; Biomarkers; Body Mass Index; Bone Density Conservation Agents; Disease Models, | 2013 |
Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bony Callus; Densitometry; Disease Models, Animal; Fe | 2013 |
Methionine down-regulates TLR4/MyD88/NF-κB signalling in osteoclast precursors to reduce bone loss during osteoporosis.
Topics: Acid Phosphatase; Administration, Oral; Alendronate; Animals; Bone Density; Bone Density Conservatio | 2014 |
Synergistic antiosteoporotic effect of Lepidium sativum and alendronate in glucocorticoid-induced osteoporosis in Wistar rats.
Topics: Alendronate; Animals; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Calcium; Disease | 2013 |
Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcitriol; C | 2014 |
Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice.
Topics: Acid Phosphatase; Alendronate; Animals; Diphosphonates; Disease Models, Animal; Female; Isoenzymes; | 2015 |
Influence of alendronate administration regimen on the final outcome of implant osseointegration in an osteoporotic model.
Topics: Alendronate; Animals; Bone Cements; Bone Density Conservation Agents; Calcium Phosphates; Dexamethas | 2014 |
Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Drug E | 2014 |
Technical advance: liposomal alendronate depletes monocytes and macrophages in the nonhuman primate model of human disease.
Topics: Alendronate; Animals; Bone Marrow; Cell Count; Cell Movement; Cell Separation; Disease Models, Anima | 2014 |
Adaptive growth factor delivery from a polyelectrolyte coating promotes synergistic bone tissue repair and reconstruction.
Topics: Alendronate; Angiogenesis Inducing Agents; Animals; Becaplermin; Biocompatible Materials; Bone and B | 2014 |
An NMR metabolomic study on the effect of alendronate in ovariectomized mice.
Topics: Alendronate; Animals; Bone Density; Disease Models, Animal; Female; Glucose; Humans; Inactivation, M | 2014 |
Alterations in collagen and mineral nanostructure observed in osteoporosis and pharmaceutical treatments using simultaneous small- and wide-angle X-ray scattering.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Collagen; Disease Models, An | 2014 |
The standardized BHH10 extract, a combination of Astragalus membranaceus, Cinnamomum cassia, and Phellodendron amurense, reverses bone mass and metabolism in a rat model of postmenopausal osteoporosis.
Topics: Alendronate; Animals; Astragalus propinquus; Body Weight; Bone Density; Bone Resorption; Cinnamomum | 2015 |
Preventive effects of withaferin A isolated from the leaves of an Indian medicinal plant Withania somnifera (L.): comparisons with 17-β-estradiol and alendronate.
Topics: Acid Phosphatase; Alendronate; Animals; Biomarkers; Bone and Bones; Disease Models, Animal; Dose-Res | 2015 |
Preparation of an injectable depot system for long-term delivery of alendronate and evaluation of its anti-osteoporotic effect in an ovariectomized rat model.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Del | 2015 |
Alendronate rescued osteoporotic phenotype in a model of glucocorticoid-induced osteoporosis in adult zebrafish scale.
Topics: Acid Phosphatase; Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bone Density Conservation | 2015 |
Perioperative alendronate, risedronate, calcitonin and indomethacin treatment alters femoral stem fixation and periprosthetic bone mineral density in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, | 2015 |
Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen; Dis | 2015 |
In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Disease Model | 2016 |
An osteonecrosis model induced by oral bisphosphonate in ovariectomised rats.
Topics: Administration, Oral; Alendronate; Animals; Bone Density Conservation Agents; Disease Models, Animal | 2015 |
Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer.
Topics: Alendronate; Animals; Antibiotics, Antineoplastic; Bone Density Conservation Agents; Bone Neoplasms; | 2015 |
The determination of apoptosis rates on articular cartilages of ovariectomized rats with and without alendronate treatment.
Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Cartilage, Articular; Disease Mod | 2016 |
Metabolite Profiling Reveals the Effect of Dietary Rubus coreanus Vinegar on Ovariectomy-Induced Osteoporosis in a Rat Model.
Topics: Acetic Acid; Alendronate; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; | 2016 |
Experimental osteonecrosis: development of a model in rodents administered alendronate.
Topics: Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bisphosphonate-Associated Osteonecrosis of t | 2016 |
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Disease Models, Animal; Dru | 2017 |
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Topics: Alendronate; Alkaline Phosphatase; Anastrozole; Animals; Aromatase Inhibitors; Bone Density; Bone De | 2017 |
Alendronate inhibits hyperalgesia and suppresses neuropeptide markers of pain in a mouse model of osteoporosis.
Topics: Alendronate; Animals; Biomarkers; Bone Density Conservation Agents; Calcitonin Gene-Related Peptide; | 2017 |
Local action of sodium alendronate in bone repair of spontaneously hypertensive rat (SHR).
Topics: Alendronate; Analysis of Variance; Animals; Bone Density Conservation Agents; Bone Regeneration; Dis | 2008 |
Effect of low-power gallium-aluminum-arsenium laser therapy (830 nm) in combination with bisphosphonate treatment on osteopenic bone structure: an experimental animal study.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality | 2009 |
Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Dose-R | 2008 |
The effects of alendronate in the treatment of experimental osteonecrosis of the hip in adult rabbits.
Topics: Acetabulum; Adult; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remode | 2009 |
Peritoneal macrophage depletion by liposomal bisphosphonate attenuates endometriosis in the rat model.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Chemokine CCL2; Cytokines; Disease Models, A | 2009 |
Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined | 2008 |
Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.
Topics: Alendronate; Animals; Computer Simulation; Disease Models, Animal; Dogs; Etidronic Acid; Fractures, | 2009 |
Biocompatibility evaluation of alendronate paste in rat's subcutaneous tissue.
Topics: Alendronate; Animals; Biocompatible Materials; Disease Models, Animal; Injections, Subcutaneous; Mal | 2009 |
Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate.
Topics: Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bone Density; Bone Density Conservation Agen | 2009 |
Alendronate treatment improves bone-pedicle screw interface fixation in posterior lateral spine fusion: an experimental study in a porcine model.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Screws; Bone T | 2010 |
Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Resorption; Diphosphonates; Dise | 2009 |
Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Disease Models, Ani | 2009 |
Experimental results of combining bisphosphonates with allograft in a rat model.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Bone Transpla | 2009 |
Mandibular necrosis in beagle dogs treated with bisphosphonates.
Topics: Alendronate; Alveolar Process; Animals; Bone Density Conservation Agents; Bone Matrix; Bone Remodeli | 2009 |
Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis?
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Plates; Bone Regeneration; Bony Callus; | 2010 |
[Skeletal biomechanical effectiveness of retinoic acid on induction of osteoporotic rats treated by alendronate and qianggu capsules].
Topics: Alendronate; Animals; Biomechanical Phenomena; Disease Models, Animal; Drugs, Chinese Herbal; Female | 2009 |
Vibrational bone characteristics versus bone density for the assessment of osteoporosis in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Disease Models, Animal; Female; Fourier Analysis; Linear Models; | 2010 |
Comparison of the effects of alendronate sodium and calcitonin on bone-prosthesis osseointegration in osteoporotic rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcitonin; Disease Models, An | 2011 |
Comment on Xue et al.: Alendronate treatment improves bone-pedicle screw interface fixation in posterior lateral spine fusion: an experimental study in a porcine model.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Bone Screws; Disease Models | 2010 |
Effective dosage and administration schedule of oral alendronate for non-nociceptive symptoms in rats with chronic constriction injury.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Complex Regional Pain Synd | 2010 |
In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat.
Topics: Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Dis | 2010 |
Effect of alendronate on alveolar bone resorption and angiogenesis in rats with experimental periapical lesions.
Topics: Acid Phosphatase; Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Bone Density Conservat | 2010 |
Osteogenic activity of locally applied small molecule drugs in a rat femur defect model.
Topics: Alendronate; Animals; Bone Density; Disease Models, Animal; Femur; Lovastatin; Male; Omeprazole; Org | 2010 |
[Comparison of effects of Wujia Bugu decoction) and alendronate sodium on protection the bone loss of hindlimb unloaded rats].
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Disease Models, Animal; Drugs, Chinese Herbal; | 2010 |
Evaluation of a novel osteoporotic drug delivery system in vitro: alendronate-loaded calcium phosphate cement.
Topics: Alendronate; Animals; Bone Cements; Bone Density Conservation Agents; Calcium Phosphates; Cell Proli | 2010 |
Route of administration-dependent anti-inflammatory effect of liposomal alendronate.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Carotid Stenosis; Chemistry, Pharmaceutical; Disease | 2010 |
Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Drug | 2011 |
Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.
Topics: Alendronate; Animals; Aorta; Aortic Aneurysm; Bone Diseases, Metabolic; Bone Morphogenetic Proteins; | 2010 |
The effect of oestrogen and alendronate therapies on postmenopausal bone loss around osseointegrated titanium implants.
Topics: Absorptiometry, Photon; Alendronate; Amino Acids; Animals; Biomarkers; Bone Density; Bone Density Co | 2011 |
The influence of alendronate on spine fusion in an osteoporotic animal model.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Transplantatio | 2011 |
Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritis.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservatio | 2011 |
Synthesis and in vivo bioactivity of lipophilic alendronate derivatives against osteoporosis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Chromatography, High Pressure Liquid; Diseas | 2011 |
Efficacy of serotonin inhibition in mouse models of bone loss.
Topics: Aging; Alendronate; Animals; Bone and Bones; Bone Resorption; Disease Models, Animal; Dose-Response | 2011 |
Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
Topics: Acid Phosphatase; Alendronate; Animals; Antibodies, Monoclonal; Bone and Bones; Bone Density; Bone D | 2011 |
Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
Topics: Acid Phosphatase; Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conserva | 2012 |
Antiosteoporotic activity of Davallia formosana.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone | 2012 |
Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; | 2012 |
Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats.
Topics: Alendronate; Animals; Benzoates; Bone Density; Bone Density Conservation Agents; Bone Diseases, Meta | 2012 |
Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: evaluation of transdermal absorption, safety, and pharmacological effects after application in rats.
Topics: Administration, Cutaneous; Alendronate; Animals; Biological Availability; Bone Density Conservation | 2012 |
Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis.
Topics: Alendronate; Animals; Anterior Cruciate Ligament Injuries; Benzamides; Biomarkers; Bone Density Cons | 2012 |
Downregulation of the inflammatory response by CORM-3 results in protective effects in a model of postmenopausal arthritis.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Arthritis; Biomarkers; Disease Models, Animal; Down- | 2012 |
Peri-implant and systemic effects of high-/low-affinity bisphosphonate-hydroxyapatite composite coatings in a rabbit model with peri-implant high bone turnover.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Coated Materials, Biocompatible; Disease Mod | 2012 |
Alendronate enhances osseous healing in a rat calvarial defect model.
Topics: Alendronate; Analysis of Variance; Animals; Bone Density Conservation Agents; Bone Transplantation; | 2012 |
Heparanase role in the treatment of avascular necrosis of femur head.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Combined Modality Therapy; Decompression, Su | 2013 |
Unfocused extracorporeal shock waves induce anabolic effects in osteoporotic rats.
Topics: Alendronate; Anabolic Agents; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Co | 2013 |
Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents.
Topics: Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bisphosphonate-Associated Osteonecrosis of t | 2013 |
Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Collagen Type I; Diseas | 2002 |
Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Calcification, Physiologic; Disease Models, Anim | 2003 |
The influence of alendronate on bone formation and resorption in a rat ectopic bone development model.
Topics: Alendronate; Analysis of Variance; Animals; Bone Density; Bone Diseases, Metabolic; Bone Marrow; Bon | 2003 |
Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta.
Topics: Alendronate; Animals; Bone Development; Disease Models, Animal; Dose-Response Relationship, Drug; Fe | 2003 |
A rat model for testing pharmacologic treatments of pressure-related bone loss.
Topics: Alendronate; Animals; Antirheumatic Agents; Bone Plates; Bone Resorption; Disease Models, Animal; Dr | 2003 |
A histopathological investigation on the effect of systemic administration of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the rat mandible.
Topics: Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Bone Resorption; Chi-Square Distribution | 2003 |
Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits.
Topics: Alendronate; Animals; Cell Count; Cell Division; Cell Movement; Diet, Atherogenic; Disease Models, A | 2003 |
Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening.
Topics: Administration, Topical; Alendronate; Animals; Disease Models, Animal; Male; Movement; Osteolysis; P | 2004 |
The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model.
Topics: Acid Phosphatase; Alendronate; Animals; Anterior Cruciate Ligament; Bone Remodeling; Calcinosis; Car | 2004 |
Effects of D-003, a mixture of high molecular weight aliphatic acids from sugar cane wax, on bones from ovariectomized rats.
Topics: Administration, Oral; Alendronate; Animals; Bone Density; Disease Models, Animal; Dose-Response Rela | 2004 |
Healing properties of allograft from alendronate-treated animal in lumbar spine interbody cage fusion.
Topics: Alendronate; Analysis of Variance; Animals; Biopsy, Needle; Bone Transplantation; Disease Models, An | 2005 |
High-dose alendronate uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model.
Topics: Alendronate; Analysis of Variance; Animals; Chi-Square Distribution; Disease Models, Animal; Dose-Re | 2004 |
Alendronate inhibits bone resorption at the bone-screw interface.
Topics: Acid Phosphatase; Alendronate; Animals; Bone Resorption; Bone Screws; Cathepsin K; Cathepsins; Disea | 2005 |
Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Disease Models, Animal; Fractures, Bone; Mice; O | 2005 |
Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice.
Topics: Alendronate; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Carotid Stenosis; Diphosphonates; | 2005 |
Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model.
Topics: Absorptiometry, Photon; Alendronate; Analysis of Variance; Animals; Bone and Bones; Bone Density; Ca | 2005 |
The influence of alendronate treatment and bone graft volume on posterior lateral spine fusion in a porcine model.
Topics: Administration, Oral; Alendronate; Animals; Bone Density Conservation Agents; Bone Transplantation; | 2005 |
Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
Topics: Alendronate; Animals; Apoptosis; Arthritis, Experimental; bcl-X Protein; Bone Marrow Cells; Cell Sur | 2005 |
Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Topics: Alendronate; Alkaline Phosphatase; Animals; Bone Morphogenetic Proteins; Bone Resorption; Cattle; Ch | 2005 |
Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.
Topics: Absorptiometry, Photon; Aging; Alendronate; Animals; Bone and Bones; Bone Density Conservation Agent | 2007 |
Alendronate enhances antibiotic-impregnated bone grafts in the treatment of osteomyelitis.
Topics: Alendronate; Animals; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Transplantation; | 2008 |
Alendronate therapy in cyclosporine-induced alveolar bone loss in rats.
Topics: Acid Phosphatase; Alendronate; Alkaline Phosphatase; Alveolar Bone Loss; Alveolar Process; Animals; | 2007 |
Antiangiogenic effects of bisphosphonates on laser-induced choroidal neovascularization in mice.
Topics: Alendronate; Angiogenesis Inhibitors; Animals; Cell Culture Techniques; Choroid; Choroidal Neovascul | 2007 |
The effects of bone remodeling inhibition by alendronate on three-dimensional microarchitecture of subchondral bone tissues in guinea pig primary osteoarthrosis.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodelin | 2008 |
Effect of preoperative combined treatment with alendronate and calcitriol on fixation of hydroxyapatite-coated implants in ovariectomized rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcit | 2008 |
Beneficial effects of combined administration of alendronate and alfacalcidol on cancellous bone mass of the tibia in orchidectomized rats: a bone histomorphometry study.
Topics: Alendronate; Animals; Body Weight; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone | 2008 |
Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Acyclic Monoterpenes; Alendronate; Animals; Disease Models, Anima | 2008 |
Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.
Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Diphosphonates; Dis | 2008 |
Effect of ovariectomy and alendronate on implant osseointegration in rat maxillary bone.
Topics: Alendronate; Analysis of Variance; Animals; Bone Density; Bone Density Conservation Agents; Dental I | 2008 |
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Resorption; Calcium; Carbon Radioisotope | 1995 |
Alendronate treatment of naturally-occurring periodontitis in beagle dogs.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Animals; Diphosphonates; Disease Models, Anim | 1995 |
The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats.
Topics: Alendronate; Animals; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Diphosphonates; Di | 1993 |
Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Calcium, Dietary; Clodronic Acid; Diphosphonates; Di | 1996 |
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Topics: Alendronate; Amino Acids; Animals; Biomarkers; Body Weight; Bone Resorption; Cholesterol; Disease Mo | 1996 |
Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice.
Topics: Alendronate; Animals; Antibodies, Monoclonal; Antigens; Bone Marrow; Bone Marrow Cells; Bone Resorpt | 1997 |
Alendronate prevents cyclosporin A-induced osteopenia in the rat.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Body Weight; Bone Diseases, Metabo | 1997 |
Alendronate: preclinical studies.
Topics: Alendronate; Animals; Bone Density; Bone Remodeling; Bone Resorption; Disease Models, Animal; Female | 1997 |
Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats.
Topics: Alendronate; Animals; Bone Resorption; Calcium; Calcium Oxalate; Calcium Phosphates; Calcium, Dietar | 1999 |
Alendronate did not inhibit instability-induced bone resorption. A study in rats.
Topics: Alendronate; Animals; Bone Plates; Bone Resorption; Disease Models, Animal; Drug Evaluation, Preclin | 1999 |
Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats.
Topics: Administration, Buccal; Administration, Oral; Administration, Topical; Alendronate; Alveolar Bone Lo | 2000 |
The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model.
Topics: Administration, Topical; Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Chi-Square Dist | 2000 |
Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis.
Topics: Alendronate; Animals; Arthritis; Arthroplasty; Cell Division; Disease Models, Animal; Female; Male; | 2000 |
Effect of 17beta-estradiol or alendronate on the bone densitometry, bone histomorphometry and bone metabolism of ovariectomized rats.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Densitometry; Disease Models, Animal; Estradiol; | 2001 |
Effect of topical alendronate on root resorption of dried replanted dog teeth.
Topics: Administration, Topical; Alendronate; Animals; Ankylosis; Bicuspid; Chi-Square Distribution; Dental | 2001 |
A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta.
Topics: Alendronate; Animals; Bone and Bones; Bone Development; Collagen; Disease Models, Animal; Fractures, | 2001 |
The effect of alendronate (Fosamax) and implant surface on bone integration and remodeling in a canine model.
Topics: Alendronate; Animals; Arthroplasty, Replacement, Hip; Bone Plates; Bone Remodeling; Disease Models, | 2001 |
Sintered dicalcium pyrophosphate increases bone mass in ovariectomized rats.
Topics: Administration, Oral; Alendronate; Alkaline Phosphatase; Animals; Bone Density; Calcium Pyrophosphat | 2002 |
Inhibition of particulate debris-induced osteolysis by alendronate in a rat model.
Topics: Alendronate; Animals; Disease Models, Animal; Male; Osteolysis; Polymethyl Methacrylate; Prostheses | 2002 |
[The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model].
Topics: Alendronate; Alveolar Process; Animals; Bone Density; Bone Resorption; Calcium; Disease Models, Anim | 2001 |
Effects of alendronate on particle-induced osteolysis in a rat model.
Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Disease Models, Animal; Injections, Intra-Art | 2002 |
Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats.
Topics: Alendronate; Animals; Bone Plates; Bone Resorption; Clodronic Acid; Diphosphonates; Disease Models, | 2002 |
Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment.
Topics: Alendronate; alpha-Fetoproteins; Animals; Bone and Bones; Bone Remodeling; Bone Resorption; Calciton | 2002 |
The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons.
Topics: Acid Phosphatase; Alendronate; Analysis of Variance; Animals; Bone and Bones; Bone Density; Calcium; | 1992 |
Effect of alendronate (bisphosphonate) in animal models of hyperparathyroidism.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Calcium; Diphosphonates; Disease Models, Animal | 1991 |